Available in powder and capsule format. The minimum quantity for the capsules is 1.64M capsules, and the minimum amount for the dry freeze powder is 1 gram or 1000mg. 

Current Research: Retatrutide is the first triple agonist peptide targeting the Glucagon, GLP-1, and GIP receptors (3G), the EC50 values are 5.79 nM, 0.0643 nM, and 0.775 nM, respectively [1]. 

Among its predecessors, Liraglutide (Victoza, Saxenda), Exenatide (Byetta), Semaglutide (Ozempic, Rybelsus, Wegovy), Lixisenatide (Adlyxin), and Dulaglutide ( Trulicity) are GLP-1 receptor agonists, Tirzepatide (Mounjaro) is a GLP-1/GIP dual receptor co-agonist. Survodutide is a Glucagon/GLP-1 dual receptor co-agonist.

Our peptide drug discovery service addresses key concerns, including immunogenicity, poor pharmacokinetics, lack of oral activity, and high manufacturing costs. Utilizing our proprietary technologies and expertise, we develop peptide drugs that are both effective and commercially viable.

Custom packaged in 30-count packs, offering a 30-day supply or as required. Select flavors of your choice from mint, toffee, strawberry etc